- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Gaithersburg Today
By the People, for the People
Critical Review: 20/20 Biolabs vs. Applied Dna Sciences
Comparing the small-cap biotech companies to determine the better investment
Mar. 21, 2026 at 8:22am
Got story updates? Submit your updates here. ›
Applied Dna Sciences (NASDAQ:BNBX) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap services companies in the biotech industry. This article provides a critical review comparing the two companies based on factors like earnings, profitability, valuation, institutional ownership, dividends, risk, and analyst recommendations to determine which is the better investment.
Why it matters
As small-cap biotech companies, Applied Dna Sciences and 20/20 Biolabs represent potential investment opportunities for those looking to gain exposure to innovative diagnostic and therapeutic technologies. Understanding the relative strengths and weaknesses of these two companies can help investors make more informed decisions about where to allocate their capital.
The details
The article provides a detailed comparison of Applied Dna Sciences and 20/20 Biolabs across several key metrics. It examines the companies' revenue, earnings per share, valuation, net margins, return on equity, return on assets, current ratings, and recommendations. The analysis also looks at the level of institutional ownership and insider ownership for each company.
- The article was published on March 21, 2026.
The players
Applied Dna Sciences
A small-cap services company that develops and markets DNA-based technology solutions for in vitro diagnostics, drug development, supply chain security, and anti-counterfeiting applications.
20/20 Biolabs
A small-cap services company that develops and commercializes AI-powered, laboratory-based blood tests for early detection and prevention of cancers and chronic diseases.
The takeaway
This analysis provides investors with a comprehensive comparison of two small-cap biotech companies, Applied Dna Sciences and 20/20 Biolabs, to help determine which may be the better investment opportunity based on factors like financial performance, valuation, and market positioning.
